Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.49 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.49 |
| ▸ | ITGAL | P20701 | 2/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | PTGFR | P43088 | 1/20 | 0.49 |
| ▸ | PTGIR | P43119 | 1/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.49 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5243906 | 1.00 | MAPT (0.49) | MAPTITGB2ICAM1ITGALPTGER3 | |
| SCHEMBL8123761 | 0.86 | ITGB2 (0.49) | MAPTITGB2ICAM1ITGALPTGER3 | |
| SCHEMBL8123759 | 0.86 | ITGB2 (0.49) | MAPTITGB2ICAM1ITGALPTGER3 | |
| SCHEMBL165227 | 0.81 | MAPT (0.65) | MAPTITGB2ICAM1ITGALPTGER3 | |
| SCHEMBL29419102 | 0.81 | MAPT (0.65) | MAPTITGB2ICAM1ITGALPTGER3 | |
| SCHEMBL481451 | 0.81 | MAPT (0.65) | MAPTITGB2ICAM1ITGALPTGER3 | |
| SCHEMBL3179934 | 0.80 | ABL1 (0.51) | MAPTALDH1A1KDM4EGAAL3MBTL1 | |
| SCHEMBL3179944 | 0.80 | ABL1 (0.51) | MAPTALDH1A1KDM4EGAAL3MBTL1 | |
| SCHEMBL11459860 | 0.80 | MAPT (0.63) | MAPTITGB2ICAM1ITGALPTGER3 | |
| Hydrochloric Acid SCHEMBL6822024 | 0.80 | MAPT (0.63) | MAPTITGB2ICAM1ITGALPTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | VALO HEALTH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20220073452-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO HEALTH, INC. | 2022-03-10 | — | — | US | disclosed |
| EP-3932914-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Valo Health, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| US-10988441-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200331847-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO HEALTH, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10508077-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-12-17 | — | — | US | disclosed |
| US-20190241506-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO HEALTH, INC. | 2019-08-08 | — | — | US | disclosed |
| US-10266487-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180297939-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Valo Health, LLC | 2018-10-18 | — | — | US | disclosed |
| US-9745253-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160264518-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Valo Health, LLC | 2016-09-15 | — | — | US | disclosed |
| US-8729095-B2 | 3-(biaryloxy)propionic acid derivatives for prevention and/or treatment of thromboembolic diseases | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-20 | — | — | US | disclosed |
| US-20120245152-A1 | 3-(BIARYOXY)PROPIONIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-2471792-A1 | 3-(BIARYLOXY) PROPIONIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| EP-1794164-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCR1 ANTAGONISTS | Novartis AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| WO-2005103054-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCRI ANTAGONISTS | NOVARTIS AG (CH) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245152-A1 | 3-(BIARYOXY)PROPIONIC ACID DERIVATIVE | F11, PF4, F2 | MAPT 4850/4885ITGB2 1196/4885ICAM1 1512/4885 |
| US-20220073452-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | MAPT 1332/4885ITGB2 1881/4885ICAM1 2116/4885 |
| US-20200331847-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | MAPT 1332/4885ITGB2 1881/4885ICAM1 2116/4885 |
| US-10988441-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | MAPT 1332/4885ITGB2 1881/4885ICAM1 2116/4885 |
| US-20160264518-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | MAPT 1332/4885ITGB2 1881/4885ICAM1 2116/4885 |
| US-10508077-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | MAPT 1332/4885ITGB2 1881/4885ICAM1 2116/4885 |
| US-10266487-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | MAPT 1332/4885ITGB2 1881/4885ICAM1 2116/4885 |
| US-20190241506-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | MAPT 1332/4885ITGB2 1881/4885ICAM1 2116/4885 |
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | MAPT 1332/4885ITGB2 1881/4885ICAM1 2116/4885 |
| US-20180297939-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | MAPT 1332/4885ITGB2 1881/4885ICAM1 2116/4885 |
| US-20070196270-A1 | Compounds As Ccri Antagonists | CCR1, CCR10, CCR4 | MAPT 2220/4885ITGB2 1305/4885ICAM1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.